205 related articles for article (PubMed ID: 24077964)
1. Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice.
Lapinski PE; Meyer MF; Feng GS; Kamiya N; King PD
Dis Model Mech; 2013 Nov; 6(6):1448-58. PubMed ID: 24077964
[TBL] [Abstract][Full Text] [Related]
2. Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations.
Bauler TJ; Kamiya N; Lapinski PE; Langewisch E; Mishina Y; Wilkinson JE; Feng GS; King PD
Dis Model Mech; 2011 Mar; 4(2):228-39. PubMed ID: 21068439
[TBL] [Abstract][Full Text] [Related]
3. Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Kamiya N; Kim HK; King PD
Bone; 2014 Dec; 69():55-60. PubMed ID: 25178522
[TBL] [Abstract][Full Text] [Related]
4. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Yang W; Wang J; Moore DC; Liang H; Dooner M; Wu Q; Terek R; Chen Q; Ehrlich MG; Quesenberry PJ; Neel BG
Nature; 2013 Jul; 499(7459):491-5. PubMed ID: 23863940
[TBL] [Abstract][Full Text] [Related]
5. Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis.
Wang S; Yu WM; Zhang W; McCrae KR; Neel BG; Qu CK
J Biol Chem; 2009 Jan; 284(2):913-20. PubMed ID: 19008228
[TBL] [Abstract][Full Text] [Related]
6. Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation.
Eminaga S; Bennett AM
J Biol Chem; 2008 May; 283(22):15328-38. PubMed ID: 18378677
[TBL] [Abstract][Full Text] [Related]
7. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Xu D; Wang S; Yu WM; Chan G; Araki T; Bunting KD; Neel BG; Qu CK
Blood; 2010 Nov; 116(18):3611-21. PubMed ID: 20651068
[TBL] [Abstract][Full Text] [Related]
8. Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice.
Coulombe G; Leblanc C; Cagnol S; Maloum F; Lemieux E; Perreault N; Feng GS; Boudreau F; Rivard N
Mol Cell Biol; 2013 Jun; 33(11):2275-84. PubMed ID: 23530062
[TBL] [Abstract][Full Text] [Related]
9. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Miyamoto D; Miyamoto M; Takahashi A; Yomogita Y; Higashi H; Kondo S; Hatakeyama M
Oncogene; 2008 Jun; 27(25):3508-15. PubMed ID: 18223690
[TBL] [Abstract][Full Text] [Related]
11. The use of SHP-2 gene transduced bone marrow mesenchymal stem cells to promote osteogenic differentiation and bone defect repair in rat.
Fan D; Liu S; Jiang S; Li Z; Mo X; Ruan H; Zou GM; Fan C
J Biomed Mater Res A; 2016 Aug; 104(8):1871-81. PubMed ID: 26999642
[TBL] [Abstract][Full Text] [Related]
12. SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Langdon Y; Tandon P; Paden E; Duddy J; Taylor JM; Conlon FL
Development; 2012 Mar; 139(5):948-57. PubMed ID: 22278918
[TBL] [Abstract][Full Text] [Related]
13. SHP-2 regulates growth factor dependent vascular signalling and function.
Mannell H; Krotz F
Mini Rev Med Chem; 2014; 14(6):471-83. PubMed ID: 22512561
[TBL] [Abstract][Full Text] [Related]
14. SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates.
Bowen ME; Ayturk UM; Kurek KC; Yang W; Warman ML
PLoS Genet; 2014; 10(5):e1004364. PubMed ID: 24875294
[TBL] [Abstract][Full Text] [Related]
15. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Loh ML; Vattikuti S; Schubbert S; Reynolds MG; Carlson E; Lieuw KH; Cheng JW; Lee CM; Stokoe D; Bonifas JM; Curtiss NP; Gotlib J; Meshinchi S; Le Beau MM; Emanuel PD; Shannon KM
Blood; 2004 Mar; 103(6):2325-31. PubMed ID: 14644997
[TBL] [Abstract][Full Text] [Related]
16. Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals.
Qu CK; Yu WM; Azzarelli B; Feng GS
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8528-33. PubMed ID: 10411909
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses.
Deng Z; Ma S; Zhou H; Zang A; Fang Y; Li T; Shi H; Liu M; Du M; Taylor PR; Zhu HH; Chen J; Meng G; Li F; Chen C; Zhang Y; Jia XM; Lin X; Zhang X; Pearlman E; Li X; Feng GS; Xiao H
Nat Immunol; 2015 Jun; 16(6):642-52. PubMed ID: 25915733
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration.
Gagné-Sansfacon J; Langlois A; Langlois MJ; Coulombe G; Tremblay S; Vaillancourt-Lavigueur V; Qu CK; Menendez A; Rivard N
J Pathol; 2019 Jan; 247(1):135-146. PubMed ID: 30376595
[TBL] [Abstract][Full Text] [Related]
19. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Uhlén P; Burch PM; Zito CI; Estrada M; Ehrlich BE; Bennett AM
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2160-5. PubMed ID: 16461457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
